(Q39418724)

11 September 2017

title

TP53INP1 as new therapeutic target in castration-resistant prostate cancer (English)

1 reference

11 September 2017

1 reference

Sophie Giusiano

1

1 reference

11 September 2017

Virginie Baylot

2

1 reference

11 September 2017

Claudia Andrieu

3

1 reference

11 September 2017

Ladan Fazli

4

1 reference

11 September 2017

Martin Gleave

5

1 reference

11 September 2017

Juan Lucio Iovanna

6

1 reference

11 September 2017

Colette Taranger-Charpin

7

1 reference

11 September 2017

Stéphane Garcia

8

1 reference

11 September 2017

Palma Rocchi

9

1 reference

11 September 2017

publication date

27 December 2011

1 reference

11 September 2017

1 reference

11 September 2017

volume

72

1 reference

11 September 2017

issue

12

1 reference

11 September 2017

page(s)

1286-1294

1 reference

Understanding the epidemiology, natural history, and key pathways involved in prostate cancer

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Hormone-refractory prostate cancer: a shifting paradigm in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

The case for early chemotherapy for the treatment of metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

P53-dependent expression of the stress-induced protein (SIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Down-expression of tumor protein p53-induced nuclear protein 1 in human gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22477

21 January 2018

Identifiers

DOI

10.1002/PROS.22477

1 reference

11 September 2017

1 reference